Summary

Other Scenarios:

Buyer: Schering-Plough Corp. (SGP) Last Price: 18.05 Market Cap.: 26.70B
Target: Acambis plc (ADR) (ACAM) Last Price: 7.21 Market Cap.: 3.87B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 860
Biopharmaceuticals 311
Veterinary Products and Services   7
Manufacturing   1,152
Consumer Manufacturing   334

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 75)
  • Clarinex Syrup (Desloratadine)
  • Claritin (Loratadine)
  • Clarinex (Desloratadine)
  • Clarinex Reditabs (Desloratadine)
Target (Total: 9)
  • Berna Products Vivotif (Typhoid Vaccine Live Oral Ty21a)
  • Smallpox-MVA3000
  • C. difficile Vaccine
  • ChimeriVax
Buyer
  • Schering-Plough Corp.
  • Coppertone
  • Bain De Soleil
  • Solarcaine
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 32)
  • Pharmacopeia Drug Discovery, Inc. (PCOP)
  • Encysive Pharmaceuticals, Inc. (ENCY)
  • American Express Company (AXP)
  • Biogen Idec Inc (BIIB)
Target (Total: 2)
  • Baxter International Inc. (BAX)
  • Cangene Corporation
Buyer (Total: 9)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • Merck & Co., Inc. (MRK)
  • Millennium Pharmaceuticals, Inc. (MLNM)
Target (Total: 1)
  • Federal Government Agencies (United States)

Key Financial Summary:

Metric Buyer Target
Number of Employees 32,600 270
Revenue Per Employee 285,813.7 117,943.6
Total Revenue 2,323.0 8.0
Total Expenses 2,131.0 26.8
Other Revenue 0.0 0.0
Cost of Revenue 815.0 9.4
SG&A Expense 1,113.0 2.4
Research & Development 473.0 15.0
Other Operating Expense 12.0 0.0
Operating Income 192.0 -18.8
Unusual Income -14.0 0.0
Gross Margin % 64.92 -17.39
Metric Buyer Target
Operating Margin % 8.27 -234.78
Total Assets 15,469.0 229.6
Return on Equity % 6.77 -49.33
Cash+ ST Inv. Per Share 3.76 2.39
Total Debt 3,677.0 8.7
Curr Portion of LTD/Cap Lease 1,278.0 0.0
Total Debt to Equity 49.78 5.56
LT Debt to Capital 24.51 5.26
Fwd P/E 33.33 n/a
Fwd P/Rev 2.66 n/a
Book Value 5,949.0 156.6

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral > Vaccines

Business Description

Buyer

Schering-Plough Corporation (Schering-Plough) is a global science-based healthcare company with prescription, consumer and animal health products. Through internal research and collaborations with business partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough has three segments: Prescription Pharmaceuticals, Consumer Health Care and Animal Health. The Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. The Consumer Health Care segment develops, manufactures and markets over the counter (OTC), foot care and sun care products. The Animal Health segment discovers, develops, manufactures and markets animal health products.

Target

Acambis plc is a biopharmaceutical company operating in the infectious disease arena, with a focus on developing new vaccines. The Company's revenues are principally derived by sales of ACAM2000, the investigational product in its smallpox vaccine franchise, which is being sold to governments, even while it undergoes clinical testing. In addition, revenues also come from sales in North America of an oral typhoid vaccine, Vivotif by its sales and distribution operation, Berna Products Corporation. The majority of Acambis' operations are in the United States, with research and development in Cambridge, Massachusetts; manufacturing in Canton, Massachusetts; a sales and marketing operation in Miami, Florida, and a lyophilisation and fill and finish facility in Rockville, Maryland that the Company acquired in May 2005. During the year ended December 31, 2004, Acambis' customer, the United States Centres for Disease Control and Prevention, accounted for 84% of its revenues.

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Schering-Plough Corp.
  
Manufacturing  
Consumer Manufacturing  
Personal Care Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, shampoo and other toiletries.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Dermatology  
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Clarinex Syrup (Desloratadine)
  • Claritin (Loratadine)
  • Clarinex (Desloratadine)
  • Clarinex Reditabs (Desloratadine)
  
Upper Respiratory  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Chlor-Trimeton Allergy (Chlorpheniramine Maleate)
  • Clarinex (Desloratadine)
  • Claritin (Loratadine)
  • Clarinex Reditabs (Desloratadine)
  
Antihistamines/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, relieving pain, and reducing fever.

Buyer Products:

  • Coricidin HBP Cold & Flu (Acetaminophen/Chlorpheniramine Maleate)
  
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Buyer Products:

  • Coricidin HBP Cough & Cold (Chlorpheniramine Maleate/Dextromethorphan Hydrobromide)
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Buyer Products:

  • Clarinex D-12 Hour (Desloratadine/Pseudoephedrine)
  • Drixoral Cold & Allergy (Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride)
  • Claritin D (Loratadine/Pseudoephedrine)
  • Clarinex D-24 Hour (Desloratadine/Pseudoephedrine)
  • Chlor-Trimeton Allergy/Decongestant (Chlorpheniramine Maleate/Pseudoephedrine)
  
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.

Buyer Products:

  • Chlor-Trimeton Allergy-Sinus (Chlorpheniramine Maleate/Phenylpropanolamine/Acetaminophen)
  • Drixoral Allergy-Sinus (Dexbrompheniramine Maleate/Pseudoephedrine Sulfate/Acetaminophen)
  • Drixoral Cold & Flu (Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Sulfate)
  
Antihistamines/Leukotriene Receptor Antagonists
Therapeutics that treat allergic reactions by suppressing inflammation and working on certain receptors involved in the immune process.

Buyer Products:

  • Claritin (Loratadine)/Singulair (Montelukast)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.

Buyer Products:

  • Nasonex (Mometasone Furoate)
  • Vanceril (Beclomethasone Dipropionate)
  
Cardiovascular System  
Heart Disorders  
Acute Coronary Syndrome (ACS)  
Anticoagulating Agents  
Platelet Aggregation Inhibitors  
Glycoprotein IIb/IIIa Receptor Blocking Agents
Therapeutics that treat acute coronary syndrome by blocking the receptor that allows platelets to clump together.

Buyer Products:

  • Integrilin (Eptifibatide)
  
Angina  
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.

Buyer Products:

  • IMDUR (Isosorbide Mononitrate)
  • Nitro-Dur (Nitroglycerin)
  
Myocardial Infarction (MI)  
Anticoagulating Agents  
Platelet Aggregation Inhibitors  
Glycoprotein IIb/IIIa Receptor Blocking Agents
Therapeutics that treat myocardial infarction by preventing various adhesive factors from attaching to the specific receptor and causing platelet aggregation.

Buyer Products:

  • Integrilin (Eptifibatide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Integrilin (Eptifibatide)
  • Thrombin Inhibitor
  
Vascular Disorders  
Hypertension  
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.

Buyer Products:

  • Hyperstat (Diazoxide)
  • Nitro-Dur (Nitroglycerin)
  
Dermatology  
Lesion/Scaling Disorders  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Diprolene Series (Betamethasone Dipropionate)
  • Elocon (Mometasone Furoate)
  
Diaper Rash  
Zinc Oxide
Therapeutics that treat diaper rash by forming a protective barrier against the skin.

Buyer Products:

  • A+D Diaper Rash Cream (Zinc Oxide)
  
Pemphigus Vulgaris  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat Pemphigus Vulgaris by suppressing inflammation through inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Celestone (Glucocorticoid/Betamethasone)
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.

Buyer Products:

  • Trilafon (Perphenazine)
  
Intestinal Disorders  
Constipation  
Impacted Bowels  
Stool Softeners
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body.

Buyer Products:

  • Correctol (Bisacodyl)
  • Correctol Stool Softner (Docusate Sodium)
  
Liver Disorders  
Hepatitis  
Hepatitis B  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  
Hepatitis C  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Low Dosed PEG-Intron (Peginterferon Alfa-2b)
  • PEG-Intron RediPen (Peginterferon Alfa-2b)
  • Intron A (Interferon Alfa 2B Recombinant Human)
  • PEG-Intron A (Peginterferon Alfa-2b)
  
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.

Buyer Products:

  • Rebetol (Ribavirin)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SCH 503034
  
Endocrinology/Metabolism  
General Hormone Treatments  
Betamethasones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.

Buyer Products:

  • Celestone (Glucocorticoid/Betamethasone)
  
Intermediary Metabolism Disorders  
Hypercholesterolemia  
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol levels by inhibiting the absorption of cholesterol.

Buyer Products:

  • Zetia (Ezetimibe)
  
Cholesterol Absorption Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.

Buyer Products:

  • Vytorin (Ezetimibe/Simvastatin)
  
Hematology  
Serum Factor Disorders  
Hypercholesterolemia  
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol levels by inhibiting the absorption of cholesterol.

Buyer Products:

  • Zetia (Ezetimibe)
  
Cholesterol Absorption Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.

Buyer Products:

  • Vytorin (Ezetimibe/Simvastatin)
  
Hypokalemia  
Potassium Supplements
Therapeutics that treat hypokalemia by providing potassium to the body.

Buyer Products:

  • K-DUR 10/20 (Potassium Chloride)
  
Immunology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • CNTO 148 (Golimumab)
  • Vicriviroc (CCR5 Receptor Antagonist)
  
Infectious Diseases
Bacterial
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.

Buyer Products:

  • Garamycin (Gentamicin)
  
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Garenoxacin
  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Cipro IV (Ciprofloxacin)
  • Cipro/Cipro XR (Ciprofloxacin)
  • Avelox (Moxifloxacin)
  
Narrow Spectrum  
Respiratory System  
Pneumonia  
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Cipro IV (Ciprofloxacin)
  • Cipro/Cipro XR (Ciprofloxacin)
  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Cipro IV (Ciprofloxacin)
  • Cipro/Cipro XR (Ciprofloxacin)
  
Urology  
Prostatitis  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Cipro IV (Ciprofloxacin)
  • Cipro/Cipro XR (Ciprofloxacin)
  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Cipro IV (Ciprofloxacin)
  • Cipro/Cipro XR (Ciprofloxacin)
  
Vaccines  
Bacterial  
Single Target  
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.

Target Products:

  • Berna Products Vivotif (Typhoid Vaccine Live Oral Ty21a)
  
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Azoles  
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Noxafil (Posaconazole)
  
Narrow Spectrum  
Dermatology  
Tinea Barbae  
Penicillin Derivatives
Therapeutics that treat fungal infections of the bearded area by inhibiting the biosynthesis of cell walls.

Buyer Products:

  • Fulvicin U/F (Griseofulvin)
  
Tinea Capitis  
Penicillin Derivatives
Therapeutics that treat fungal infections of the scalp by inhibiting biosynthesis of cell walls.

Buyer Products:

  • Fulvicin U/F (Griseofulvin)
  
Tinea Corporis (Ringworm)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Lotrimin AF (Clotrimazole)
  
Imidazoles/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide and suppressing inflammation by preventing the accumulation of inflammatory cells like leukocytes and macrophages at the inflammation site.

Buyer Products:

  • Lotrisone (Clotrimazole/Betamethasone)
  
Penicillin Derivatives
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by inhibiting the biosynthesis of cell walls.

Buyer Products:

  • Fulvicin U/F (Griseofulvin)
  
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.

Buyer Products:

  • Tinactin (Tolnaftate)
  
Tinea Cruris (Jock Itch)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Lotrimin AF (Clotrimazole)
  
Imidazoles/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide and suppressing inflammation by preventing the accumulation of inflammatory cells like leukocytes and macrophages at the inflammation site.

Buyer Products:

  • Lotrisone (Clotrimazole/Betamethasone)
  
Penicillin Derivatives
Therapeutics that treat fungal infections of the groin and perineum by inhibiting the biosynthesis of cell walls.

Buyer Products:

  • Fulvicin U/F (Griseofulvin)
  
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.

Buyer Products:

  • Tinactin (Tolnaftate)
  
Tinea Pedis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Lotrimin AF (Clotrimazole)
  
Imidazoles/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide and suppressing inflammation using a steroidal compound.

Buyer Products:

  • Lotrisone (Clotrimazole/Betamethasone)
  
Penicillin Derivatives
Therapeutics that treat fungal infections of the feet by inhibiting the biosynthesis of cell walls.

Buyer Products:

  • Fulvicin U/F (Griseofulvin)
  
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.

Buyer Products:

  • Tinactin (Tolnaftate)
  
Tinea Unquium  
Penicillin Derivatives
Therapeutics that treat fungal infections of the nails by inhibiting the biosynthesis of cell walls.

Buyer Products:

  • Fulvicin U/F (Griseofulvin)
  
Tinea Versicolor  
Penicillin Derivatives
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by inhibiting the biosynthesis of cell walls.

Buyer Products:

  • Fulvicin U/F (Griseofulvin)
  
Urology  
Vaginal Candidiasis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Gyne-Lotrimin (Clotrimazole)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • Pleconaril
  • SCH 503034
  • Vicriviroc (CCR5 Receptor Antagonist)

Target Products:

  • Smallpox-MVA3000
  • C. difficile Vaccine
  • ChimeriVax
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Target Products:

  • Hyperimmune Globulin
  • Influenza Vaccine Program
  
Viral
DNA Viruses  
Hepadnavirus  
Hepatitis B  
Chronic  
Interferons
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months with natural proteins that have antiviral activity.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  
Papillomavirus  
Verrucae (Warts)  
Interferons
Therapeutics that treat warts by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  
RNA Viruses  
Flavivirus  
Hepatitis C  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Low Dosed PEG-Intron (Peginterferon Alfa-2b)
  • PEG-Intron RediPen (Peginterferon Alfa-2b)
  • PEG-Intron A (Peginterferon Alfa-2b)
  • Intron A (Interferon Alfa 2B Recombinant Human)
  
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.

Buyer Products:

  • Rebetol (Ribavirin)
  
Vaccines  
Viral  
Single Target  
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.

Target Products:

  • ChimeriVax
  
Variola (Smallpox)
Therapeutics that prevent or treat viral infections that cause a diffuse and extensive distribution of lesions by producing or artificially increasing immunity to the Variola virus.

Target Products:

  • Vaccinia Immune Globulin (VIG)
  • Smallpox-ACAM2000
  
Yellow Fever
Therapeutics that prevent or treat viral infections characterized by fever and hemorrhage by producing or artificially increasing immunity to the yellow fever virus.

Target Products:

  • Arilvax
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • CNTO 148 (Golimumab)
  
Neurology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Adenosine 2a Receptor Antagonist
  
Psychiatric Disorders  
Schizophrenia  
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.

Buyer Products:

  • Trilafon (Perphenazine)
  
Oncology  
Dermatology  
Kaposi`s Sarcoma  
Interferons
Therapeutics that treat and manage cancers of spindle cells by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  
Malignant Melanoma  
Interferons
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  • PEG-Intron A (Peginterferon Alfa-2b)
  
Hematology  
Leukemia  
Lymphoid  
Chronic  
Hairy Cell  
Interferons
A recombinantly produced protein normally produced by the body to fight viral infection used to treat and manage a slowly progressing cancer of lymphoid cells characterized by numerous irregular cytoplasmic projections.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  
Myeloid  
Chronic  
Myelogenous (CML)  
Interferons
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  
Lymphoma  
Non-Hodgkin`s Lymphoma (NHL)  
Interferons
Therapeutics that treat and manage lymphomas of B-cells and T-cells by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Intron A (Interferon Alfa 2B Recombinant Human)
  
Neurology  
Brain Cancer  
Glioma  
Astrocytoma  
Alkylating Agents  
Imidazotetrazines
Therapeutics that treat and manage cancer of the astrocyte cells in the brain and spinal cord.

Buyer Products:

  • Temodar (Temozolomide)
  
Glioblastoma  
Alkylating Agents  
Imidazotetrazines
Therapeutics that treat and manage cancer of the glial cells.

Buyer Products:

  • Temodar (Temozolomide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Sarasar (Lonafarnib)
  • PEG-Intron A (Peginterferon Alfa-2b)
  
Urology  
Prostate Cancer  
Metastatic  
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.

Buyer Products:

  • Eulexin (Flutamide)
  
Ophthalmology  
Degenerative Disorders  
Irritation/Inflammation  
Vasoconstricting Agents
Therapeutics that prevent inflammation by constricting the blood vessels.

Buyer Products:

  • OcuClear (Oxymetazoline)
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Acute Treatments  
Bronchodilators  
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Buyer Products:

  • Foradil Aerolizer (Formoterol)
  • Proventil/Proventil HFA (Albuterol Sulfate)
  
Prophylactic Treatments  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.

Buyer Products:

  • Asmanex Twisthaler (Mometasone Furoate)
  • Vanceril (Beclomethasone Dipropionate)
  
Bronchitis  
Acute Treatments  
Bronchodilators  
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Buyer Products:

  • Proventil/Proventil HFA (Albuterol Sulfate)
  
Bronchospasm  
Bronchodilators  
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Buyer Products:

  • Foradil Aerolizer (Formoterol)
  • Proventil/Proventil HFA (Albuterol Sulfate)
  
Chronic Obstructive Pulmonary Disease (COPD)  
Acute Treatments  
Bronchodilators  
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Buyer Products:

  • Foradil Aerolizer (Formoterol)
  • Proventil/Proventil HFA (Albuterol Sulfate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Thrombin Inhibitor
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Clarinex Syrup (Desloratadine)
  • Chlor-Trimeton Allergy (Chlorpheniramine Maleate)
  • Claritin (Loratadine)
  • Clarinex Reditabs (Desloratadine)
  • Clarinex (Desloratadine)
  
Antihistamines/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, relieving pain, and reducing fever.

Buyer Products:

  • Coricidin HBP Cold & Flu (Acetaminophen/Chlorpheniramine Maleate)
  
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Buyer Products:

  • Coricidin HBP Cough & Cold (Chlorpheniramine Maleate/Dextromethorphan Hydrobromide)
  
Antihistamines/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, preventing coughs, relieving pain, and reducing fever.

Buyer Products:

  • Coricidin HBP Maximum Strength Flu (Acetaminophen/Chlorpheniramine Maleate/Dextromethorphan)
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.

Buyer Products:

  • Clarinex D-12 Hour (Desloratadine/Pseudoephedrine)
  • Clarinex D-24 Hour (Desloratadine/Pseudoephedrine)
  • Chlor-Trimeton (Chlorpheniramine Maleate/Pseudoephedrine)
  • Drixoral Cold & Allergy (Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride)
  • Claritin D (Loratadine/Pseudoephedrine)
  
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.

Buyer Products:

  • Chlor-Trimeton Allergy-Sinus (Chlorpheniramine Maleate/Pseudoephedrine/Acetaminophen)
  • Drixoral Allergy-Sinus (Dexbrompheniramine/Pseudoephedrine Sulfate/Acetaminophen)
  • Drixoral Cold & Flu (Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Sulfate)
  
Antitussives
Therapeutics that relieve or prevent coughs.

Buyer Products:

  • Drixoral Cough (Dextromethorphan)
  
Antitussives/Expectorants
Therapeutics that treat coughs and colds by suppressing coughs and helping ejection of the mucous.

Buyer Products:

  • Coricidin HBP Chest Congestion & Cough (Dextromethorphan/Guaifenesin)
  
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.

Buyer Products:

  • Afrin Series (Oxymetazoline)
  • Drixoral Nasal Decongestant (Pseudoephedrine Sulfate)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.

Buyer Products:

  • Nasonex (Mometasone Furoate)
  • Vanceril (Beclomethasone Dipropionate)
  
Nasal Polyposis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the polyps in the upper respiratory tract with steroidal compounds.

Buyer Products:

  • Nasonex (Mometasone Furoate)
  
Surgery  
Cardiovascular System  
Complications  
Ischemia  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Glycoprotein IIb/IIIa Receptor Blocking Agents
These therapeutics prevent the clotting of blood before coronary artery procedures are performed through the skin.

Buyer Products:

  • Integrilin (Eptifibatide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of surgical complications in early stages of clinical research where human subject is involved.

Buyer Products:

  • Integrilin (Eptifibatide)
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • PDE 5 Inhibitor
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Schering-Plough Corp.
  
Manufacturing  
Consumer Manufacturing  
Personal Care Products  
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.

Buyer Products:

  • Coppertone
  • Bain De Soleil
  • Solarcaine
  • Dr. Scholl's
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Wyeth n/a 65,725.563 17.91 16.16 3.50 3.26 8.34
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Buyer
  Pfizer Inc. n/a 191,895.175 23.84 13.03 3.74 3.73 13.64
Johnson & Johnson n/a 175,639.871 16.93 15.76 3.48 3.26 n/a
Roche Holding Ltd. (ADR) n/a 131,799.556 29.24 28.64 4.77 n/a 7.51
Novartis AG (ADR) n/a 114,528.330 21.98 17.37 3.52 3.16 3.47
Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Abbott Laboratories n/a 67,576.455 20.20 16.94 3.03 3.03 15.17
Wyeth n/a 65,725.563 17.91 16.16 3.50 3.26 8.34
Target
  GlaxoSmithKline plc (ADR) n/a 158,330.716 19.29 18.56 4.17 4.17 28.38
sanofi-aventis (ADR) n/a 117,145.313 n/a 11.83 4.03 3.33 n/a
Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Wyeth n/a 65,725.563 17.91 16.16 3.50 3.26 8.34
Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Solvay SA (ADR) n/a 9,363.535 10.18 n/a 0.96 n/a 2.62
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Crucell N.V. (ADR) n/a 1,009.493 n/a -33.30 21.91 19.66 6.10
VaxGen, Inc. n/a 334.554 n/a -5.37 23.40 7.53 12.55
Oscient Pharmaceuticals Corporation n/a 147.874 n/a -2.06 8.78 3.14 -1.76
AVANT Immunotherapeutics, Inc. n/a 143.873 n/a n/a 29.58 14.59 7.81
Vical Incorporated n/a 140.636 n/a -5.52 11.72 8.54 1.75
SIGA Technologies, Inc. n/a 25.441 n/a -9.50 3.59 2.81 56.28
DOR BioPharma, Inc. n/a 21.763 n/a n/a 6.80 n/a 14.74
Berna Biotech AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pharmacopeia Drug Discovery, Inc. 58.00% 65.124 n/a -4.82 2.92 2.89 1.85
Encysive Pharmaceuticals, Inc. 15.10% 547.437 n/a -7.79 39.09 8.71 -51.00
American Express Company n/a 67,336.790 18.03 17.97 2.77 2.35 6.12
Biogen Idec Inc n/a 16,441.041 101.60 23.65 6.79 6.17 5.87
Publicis Groupe S.A. (ADR) n/a 7,122.364 19.67 20.42 1.53 1.47 -3.58
Cephalon, Inc. n/a 4,730.751 n/a 25.59 3.90 2.97 -7.86
Invitrogen Corporation n/a 3,701.691 26.84 17.63 3.09 2.79 -11.73
Millennium Pharmaceuticals, Inc. n/a 3,222.487 n/a n/a 5.77 6.47 6.16
Valeant Pharmaceuticals International n/a 1,806.932 n/a 69.75 2.20 1.97 n/a
Human Genome Sciences n/a 1,763.817 n/a -6.90 87.23 79.13 n/a
BearingPoint, Inc. n/a 1,763.458 n/a 78.09 0.52 0.48 -49.00
Nektar Therapeutics n/a 1,743.716 n/a -16.44 13.81 10.68 7.42
Rockwood Holdings, Inc. n/a 1,699.867 129.69 16.74 0.55 0.53 -1.30
ViroPharma Incorporated n/a 1,294.201 10.75 19.05 9.77 7.54 6.30
Matria Healthcare, Inc. n/a 808.636 47.04 29.07 4.51 2.15 4.60
Centennial Communications Corp. n/a 765.918 13.77 21.11 0.83 0.81 -0.79
iVillage Inc. n/a 607.046 64.68 37.95 6.67 5.45 7.53
Impax Laboratories Inc. n/a 526.362 1,048.34 33.63 4.67 2.95 8.97
AVANIR Pharmaceuticals n/a 485.591 n/a n/a 20.28 n/a 13.02
Ness Technologies, Inc n/a 386.452 7.16 13.43 0.68 0.81 4.19
Phase Forward Incorporated n/a 323.020 26.92 32.31 3.71 3.11 6.92
Enzon Pharmaceuticals, Inc. n/a 305.161 n/a 85.62 1.80 1.79 -2.55
Monogram Biosciences Inc. n/a 249.274 n/a n/a 5.17 n/a 7.83
Target
  Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Cangene Corporation n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  McKesson Corporation 10.00% 16,494.123 20.57 22.56 0.19 0.18 4.17
AmerisourceBergen Corp. 7.00% 9,564.722 31.53 22.55 0.17 0.17 5.14
Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Millennium Pharmaceuticals, Inc. n/a 3,222.487 n/a n/a 5.77 6.47 6.16
Brown Shoe Company, Inc. n/a 924.793 25.46 14.42 0.43 n/a 2.13
Grupo Casa Saba, S.A. (ADR) n/a 524.469 7.39 n/a 0.25 n/a 1.21
Enzon Pharmaceuticals, Inc. n/a 305.161 n/a 85.62 1.80 1.79 -2.55
BioScrip Inc. n/a 242.553 172.58 37.82 0.26 0.21 2.88
Hemispherx BioPharma, Inc n/a 160.589 n/a n/a 139.74 n/a 12.41
Target
  Federal Government Agencies (United States) 84.00% n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  GlaxoSmithKline plc (ADR) n/a 158,330.716 19.29 18.56 4.17 4.17 28.38
Novartis AG (ADR) n/a 114,528.330 21.98 17.37 3.52 3.16 3.47
Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Bayer AG (ADR) n/a 28,585.581 15.10 13.08 0.88 0.90 7.10
Genzyme Corporation n/a 17,727.230 39.55 24.92 6.48 5.52 8.61
Biogen Idec Inc n/a 16,441.041 101.60 23.65 6.79 6.17 5.87
Solvay SA (ADR) n/a 9,363.535 10.18 n/a 0.96 n/a 2.62
MedImmune, Inc. n/a 8,832.720 n/a 87.44 7.10 6.50 7.15
Sepracor Inc. n/a 5,876.948 9,362.85 36.18 7.16 4.66 -35.51
Millennium Pharmaceuticals, Inc. n/a 3,222.487 n/a n/a 5.77 6.47 6.16
Valeant Pharmaceuticals International n/a 1,806.932 n/a 69.75 2.20 1.97 n/a
Human Genome Sciences n/a 1,763.817 n/a -6.90 87.23 79.13 n/a
Nektar Therapeutics n/a 1,743.716 n/a -16.44 13.81 10.68 7.42
ViroPharma Incorporated n/a 1,294.201 10.75 19.05 9.77 7.54 6.30
Brown Shoe Company, Inc. n/a 924.793 25.46 14.42 0.43 n/a 2.13
Helen of Troy Limited n/a 594.263 11.06 13.04 1.02 1.04 9.03
Encysive Pharmaceuticals, Inc. n/a 547.437 n/a -7.79 39.09 8.71 -51.00
Impax Laboratories Inc. n/a 526.362 1,048.34 33.63 4.67 2.95 8.97
Grupo Casa Saba, S.A. (ADR) n/a 524.469 7.39 n/a 0.25 n/a 1.21
AVANIR Pharmaceuticals n/a 485.591 n/a n/a 20.28 n/a 13.02
Target
  sanofi-aventis (ADR) n/a 117,145.313 n/a 11.83 4.03 3.33 n/a
Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Cangene Corporation n/a n/a n/a n/a n/a n/a n/a
Berna Biotech AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 9,508.0 69.8 9,577.8
Other Revenue 0.0 0.0 0.0
Total Revenue 9,508.0 69.8 9,577.8
Cost of Revenue 3,346.0 43.7 3,389.7
SG&A Expense 4,374.0 11.3 4,385.3
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 1,865.0 53.4 1,918.4
Interest Expense -857.0 0.0 -857.0
Other Operating Expense 5.0 0.0 5.0
Unusual Expense (Income) 278.0 0.0 278.0
Total Expenses 9,011.0 108.4 9,119.4
Operating Income 497.0 -38.6 458.4
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 0.0 0.9 0.9
Other, Net 0.0 0.0 0.0
Income Before Taxes 497.0 -32.4 464.6
Income Taxes 228.0 -5.6 222.4
Income After Taxes 269.0 -26.8 242.2
Net Income - Excl. Xord. Items 269.0 -26.8 242.2
Net Income - Incl. Xord. Items 269.0 -26.8 242.2
Preferred Dividends -86.0 0.0 -86.0
Income Avail. to Common 183.0 -26.8 156.2
Share Items
Basic Avg. Shares Outstanding 1,478.0 53.6 1,531.6
Basic EPS - Excl. Xord. Items 0.12 -0.25 0.16
Basic EPS - Incl. Xord. Items 0.12 -0.50 0.16
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 1,487.0 53.6 1,540.6
F.D. EPS - Excl. Xord. Items 0.12 -0.52 0.16
F.D. EPS - Incl. Xord. Items 0.12 -0.52 0.16
Dividends Per Common Share 0.22 0.00 0.22
Balance Sheet
Assets
Cash and Equivalents 4,767.0 103.6 4,870.6
ST Investments 818.0 24.4 842.4
Accounts Receivable 1,479.0 24.9 1,503.9
Inventory 1,605.0 6.4 1,611.4
Prepayments and Advances 769.0 0.0 769.0
Other Current Assets 294.0 0.0 294.0
Current Assets 9,732.0 159.3 9,891.3
PPE 7,197.0 0.0 7,197.0
Accum D&A -2,710.0 0.0 -2,710.0
PPE, Net 4,487.0 36.2 4,523.2
Goodwill & Intangibles 569.0 34.1 603.1
Other Assets 0.0 0.0 0.0
Other LT Assets 681.0 0.0 681.0
Total Assets 15,469.0 229.6 15,698.6
Liabilities
Accounts Payable 1,078.0 60.0 1,138.0
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 2,090.0 0.0 2,090.0
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 1,278.0 0.0 1,278.0
Other (Current) Liabilities 213.0 0.0 213.0
Current Liab. 4,659.0 60.0 4,719.0
LT Debt 2,399.0 8.7 2,407.7
Total LT Debt 2,399.0 8.7 2,407.7
Deferred Taxes 117.0 2.8 119.8
Other LT Liab. 907.0 1.4 908.4
Total Liabilities 8,082.0 72.9 8,154.9
Shareholders Equity
Preferred Stock 1,438.0 0.0 1,438.0
Common Stock 1,015.0 18.6 1,033.6
Additional Paid in Capital 1,416.0 170.6 1,586.6
Retained Earnings 9,472.0 -32.5 9,439.5
Treasure Stock -5,438.0 0.0 -5,438.0
Other Equity -516.0 0.0 -516.0
Total Equity 7,387.0 156.6 7,543.6
Total Liab. & Equity 15,469.0 229.6 15,698.6
Shares Outstanding 1,480.0 53.6 1,533.6
Cash Flow
Operating Cash Flow
CF Net Income 269.0 -32.4 236.6
CF Depreciation 486.0 7.5 493.5
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items 26.0 1.0 27.0
Change in Working Capital 101.0 -40.2 60.8
Total Cash From Operating Activities 882.0 -64.1 817.9
Investing Cash Flow
Capital Expenditures -478.0 -7.1 -485.1
Other Investing Cash Flows 24.0 -2.8 21.2
Total Cash From Investing Activities -454.0 -9.9 -463.9
Financing Cash Flow
Dividends Paid -324.0 0.0 -324.0
Purchase Or Sale of Stock 0.0 2.3 2.3
Purchase and Retirement of Debt 900.0 118.2 1,018.2
Other Financing Cash Flow 60.0 -45.1 14.9
Total Cash From Financing Activities -633.0 69.6 -563.4
Exchange Rate Effects -12.0 0.0 -12.0
Net Change in Cash -217.0 -4.4 -221.4
Cash Taxes Paid 592.0 9.9 601.9
Cash Interest Paid 0.0 6.8 6.8